Chronic myeloid leukemia highlights from ASH 2025 include data on nilotinib vs imatinib, asciminib in second line, somatic ...

Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for ...

In the phase 2 FASCINATION trial, researchers sought to improve the rate of major molecular response 4 in patients newly diagnosed with CML.

Chronic myeloid leukemia may seem to appear suddenly, but new research shows it begins years before diagnosis with an explosive surge of growth. Scientists tracked how a single genetic accident—the ...